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Abstract
Background
To identify potential genetic risk factors associated with Sporadic Inclusion Body Myositis (sIBM).
Methods
We utilized an association based case-control approach on WES data of 30 Finnish sIBM patients and
of a control cohort (n=193). A separate Italian cohort of sIBM patients (n=12) was used for evaluation
of the results.
Results
We identified 7 SNPs in 5 genes that have an observed considerably higher frequency in Finnish sIBM
patients compared to the control population, and can confirm the previous association of the genetic
HLA region.
Conclusions
All seven identified variants could individually or in combination increase the susceptibility for sIBM.
Introduction
Sporadic inclusion body myositis (sIBM) is a complex, likely multifactorial disorder with an observed
male predominance. It is the most common form of adult onset inflammatory myopathy in the world,
with an age of onset after 45 years [1] and a reported prevalence ranging from 1 to 71 per million [2].
Characteristic clinical features of sIBM include distinct and often asymmetric slowly progressive
muscle weakness and atrophy in deep finger flexors and distal knee extensors [3]. Hand grip and lower
limb weakness is usually accompanied by dysphagia in approximately 65% of the cases [4] and loss of
quality of life at later stages of the disease [5].
Recent studies emphasize the role of clinical features and histopathological findings in diagnosing
sIBM [6, 7]. Muscle imaging is an additional diagnostic tool showing a consistent pattern of
involvement [3, 8]. Muscle biopsy shows degeneration of fibers accompanied by inflammatory
changes. These degenerative changes consist of atrophic fibers, rimmed vacuoles, congophilic
inclusions, multi-protein aggregates and mitochondrial defects with COX-negative SDH-positive
fibers[9, 10]. Endomysial lymphocyte infiltrates, predominantly CD8+ T-cells with invasion of non-
necrotic muscle fibers, account for the inflammatory changes, and upregulation of class I MHC
antigens is part of the immune response [11].
One recent hypothesis suggests that abnormal multi-protein aggregates cause the degeneration of aging
muscle fibers [12]. Additionally, genetic immunological factors could increase susceptibility for the T-
cell mediated inflammatory response [13].
The strongest reproduced association remains with the HLA antigens. HLA-DR3 and the extended 8.1
ancestral haplotype have been strongly associated with increased susceptibility for sIBM [14]. 35.2 AH
and 52.1 AH along with other alleles and haplotypes have been associated with increased risk of sIBM
in Caucasian and Japanese populations respectively [15-18].
Within the susceptibility MHC region, polymorphisms in the NOTCH4 gene have also been shown to
have association with sIBM (OR > 2) in two independent Caucasian populations [19].
Recently an intronic polymorphism in the gene TOMM40 was suggested to have a disease-modifying
effect [20]. A targeted sequencing study including 79 sIBM patients found rare VCP variants in two
unrelated patients [21].
Taking advantage of the genetically more homogenous Finnish population background, we designed a
WES based case-control study and observed an enrichment of certain specific variants in our sIBM
population, underlining the role of genetic factors in the pathology of sIBM.
Materials and Methods
Thirty patients from Finland and 12 patients from Italy were included in the study. The age of onset of
symptoms was over 40 years (mean=60.4 years) and family history was negative. The proportion of
Finnish male patients to female patients was 60% male (18) and 40% female (12). Clinical phenotype
and pathology were consistent with ENMC criteria and the diagnosis was classified as Clinico-
pathologically defined IBM [7]. Muscle MRI, performed on 24 Finnish and 11 Italian sIBM patients,
showed degenerative changes and edema in distal quadriceps femoris, and frequently in the medial
gastrocnemius muscles [8]. In seven more advanced patients in the Finnish cohort, the degenerative
findings were more widespread.
All the patients provided informed consent. The study was approved by the University of Helsinki
ethics review board. Genomic DNA was extracted from blood leucocytes using standard procedure.
Genetic and bioinformatic analysis
WES for 30 Finnish sIBM patients was performed using the SureSelect v2 (Agilent Technologies, CA,
USA). WES was performed for 94 controls using the SeqCap EZ Exome v2.0 (Roche Sequencing, CA,
USA). Publicly available exome data for 99 Finnish controls was downloaded from 1000Genomes
Project website (http://www.1000genomes.org). To counter the possible batch effects, only the
common probes between all the batches were used for the association study.
In total, the study cohort included 30 Finnish sIBM patients and 193 control samples exome-sequenced
on contemporary Illumina platforms.
For each sample, read alignment was done using BWA [22]. Duplicate reads were marked using Picard
(https://github. Com/broadinstitute/picard) and local realignment was performed using GATK [23].
Joint genotyping was done on the cohort of 223 samples using GATK GenotypeGVCFs variant
discovery tool.
Candidate gene approach
A candidate gene approach on WES data was used to investigate variants in 180 genes [24]. We filtered
out all the common variants (minor allele frequency (MAF) higher than 1%) in the 1000genome, ExAC
database and our internal control cohort.
Association study
Case-control variants were imported to GenABELv.1.6–7 [25] in R for genome-wide association
analysis. The genotypes were filtered for MAF>0.01, genotype call rate>0.90, individual call-rate>0.95
and Hardy-Weinberg equilibrium p>0.0000001 in the controls. Multidimensional scaling plots were
produced to identify outliers and population stratification. Identity-by-state values were calculated to
control for duplicate samples and unknown relatedness. Mixed model approach was selected to correct
for the relatedness between the genotyped individuals. The polygenic model was estimated using the
hierarchical generalized linear model in GenABEL [26]. Score test was used for association testing.
Association p-values were corrected for genomic inflation factor λ>1 and adjusted by Bonferroni
correction for multiple testing.
Human Splicing Finder (HSF) [27] was used to analyze the potential splicing effects.
Twelve Italian sIBM patients were used as a ‘validation cohort’ for the significant 7 identified SNPs.
All significantly enriched SNPs were confirmed by Sanger sequencing.
Results
We analyzed the WES data of the 30 Finnish sIBM patients for rare variants in the extensive list of
known myopathy disease genes [24]. No molecular findings able to explain the observed phenotype
were identified, excluding the presence of a muscular disorder due to already known genes (Table 1).
In the following case-control association study we identified 7 SNPs with a nominal p-value<0.005
enriched in the Finnish sIBM population (Figure 1).
Two of the significantly enriched SNPs were identified in the HLA region. Rs1063318 in HLA-DQB1
is a nonsynonymous change enriched 2.01 times in the sIBM case population. Similarly, rs7383287, a
synonymous variant in HLA-DOB, was enriched 2.3 times.
Three SNPs (rs2941515, rs73296109 and rs2941513) were identified in the STARD3 gene as a
haplotype. All three of them were synonymous variants and were enriched 4 times. Rs2941515 is the
last nucleotide of the coding exon 3 of STARD3. HSF predicted that rs2941515 and rs73296109 would
potentially alter an exonic splicing enhancer (ESE) site and activate an exonic cryptic activator site.
Rs8738 near the SETD4 gene is a synonymous variant enriched 3.10 times. Finally, rs11597050 is a
synonymous variant in SGPL1 enriched 4.53 times. Table 2 shows the enrichment and Odds ratio of
effect alleles of these SNPs. Aforementioned rs8738 was also enriched in the Italian cohort of sIBM
patients (allelic count: 5/24). HSF predicted that both these synonymous SNPs, rs8738 and
rs11597050, would potentially alter splicing.
Two SNPs in NOTCH4, rs115393945 (previously reported as rs443198) and rs915894 were found with
a frequency of 0.43 and 0.5 in the sIBM cohort as compared to 0.30 and 0.36 respectively in the control
population. The association of these SNPs did not reach statistical significance (p-value>0.05).
Discussion
WES data of 30 Finnish sIBM patients did not reveal any putative causative variants in 180 known
myopathy genes [24] including SQSTM1 and VCP (more than 99% bases covedered 10x or above). The
previously reported SNPs in SQSTM1 (rs104893941, rs147810437, rs11548633 and rs373585056) and
in VCP (rs140913250 and rs387906789) [28] were not found in our cohort of 30 sIBM patients. We did
not find any other rare variants in these two genes.
Thereafter, we designed a case-control based study to look for association of SNPs with a complex
multifactorial phenotype like sIBM. The genetics of the Finnish population is well suited for this kind
of approach due to its relative genetic isolation and presence of historical bottleneck effects [29]. In
Finland, the current best estimate for the prevalence of sIBM is 70 per million [30]. Our study suggests
the association of 7 SNPs with OR>2 and a nominal p-value<0.005, leading to a higher risk of sIBM in
Finnish patients. Two SNPs, rs1063318 in HLA-DQB1 and rs7383287 in HLA-DOB enriched in the
study population locate in the HLA locus. This is in concordance with the earlier published studies
associating HLA haplotypes with increased susceptibility for sIBM [15-18, 31-33].
Five other SNPs are located in the STARD3, SGPL1 and SETD4 genes. These genes are involved in
cellular processes such as methyltransferase activity, sphingolipid transport and metabolism. All these
SNPs were predicted to result in broken exonic enhancer sites, potentially altering the splicing.
In the STARD3 gene rs2941515, rs73296109 and rs2941513 represent a haplotype (about 5 kb).
Rs2941515 in particular is the last nucleotide of the coding exon 3 of the gene. STARD3 belongs to a
subfamily of lipid trafficking proteins related to the transport of cholestrol and sphingolipids [34].
Changes in this gene may suggest involvement of intra-cellular trafficking of sphingolipids and sterols
in sIBM.
Rs11597050 is located in the SGPL1 gene. SGPL1 is a protein that cleaves phosphorylated sphingoid
bases (PSBs) into fatty aldehydes and phosphoethanolamine as the final enzyme in sphingolipid
catabolism [35]. SGPL1 also elevates stress-induced ceramide production and apoptosis. Abormal
sphingolipid alterations have previosuly been observed in a wide range of muscular phenotypes[36].
Considering their important role abnormal synthesis, metabolism or degradation of sphingolipds, might
be a predisposing factor in sIBM as well as a number of disorders yet to be clearly understood [36].
The association of these 4 SNPs found in two different genes (STARD3 and SGPL1) may underline the
importance of sphingolipid metabolism and trafficking in sIBM pathology.
Rs8738 in SETD4 was found to be enriched in the Finnish and the Italian cohort of sIBM patients.
SETD4 is a gene belonging to the putative methyltransferase family and the subfamily of Set domain
containing proteins. The protein SETD4 is a cytosolic and nuclear Lysine methyltransferase involved in
cell cycle regulation [37].
A possible limitation in this study is represented by the different enrichment methods which were used
to capture the exomes of the 30 sIBM patients and 193 controls. This difference created a possibility of
batch effects when genotyping all 223 exomes together. To counter this, BAM files were generated
only for the shared probe regions, a total of 35,347 SNP markers, thus losing a small number of SNP
markers for which the association cannot be ascertained in the present design and this should be taken
into account in the subsequent studies. Whether the enriched variants identified could increase
susceptibility by themselves or in linkage disequilibrium with other risk variants also warrants further
consideration. Increasing the power by including additional cases from Finland, and for comparison
other populations, could reveal even more specific regions or genes with increased susceptibility for
sIBM.
Despite the challenges of sIBM being a complex disorder, genetic research is likely to result in
important findings for understanding the etiology of the disease. Unusual combinations of different
mutated genes in the same individual may result in higher risk of developing a multifactorial sporadic
disease like sIBM.
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Figure Legends
Figure 1: Enrichment of SNPs in sIBM
Seven enriched SNPs were identified from the case−control association study in the sIBM population. A
comparison of the frequency for each SNP in the control population and the sIBM cohort is shown here.
Tables
Table 1 List of variants found in WES data of 30 sIBM patients.
Patient Total no of variants§ Non-synonymous
and non-intronic
variants
Variants in Myocap
genes* (LOF variants)**
1 1378 778 12 (0)
2 1356 756 12 (0)
3 1404 802 12 (0)
4 1317 737 5 (0)
5 1339 743 5 (0)
6 1488 845 8 (0)
7 1385 770 15 (0)
8 1385 786 9 (1)
9 1397 763 6 (0)
10 1443 802 12 (0)
11 1440 806 7 (0)
12 1463 807 10 (0)
13 1486 820 15 (0)
14 1321 756 8 (0)
15 1393 786 7 (0)
16 1421 792 7 (0)
17 1380 765 9 (0)
18 1404 788 11 (1)
19 1455 825 17 (0)
20 1399 783 9 (0)
21 1407 805 11 (0)
22 1455 816 8 (0)
23 1428 804 15 (0)
24 1428 790 5 (0)
25 1425 829 13 (0)
26 1359 808 7 (0)
27 1417 796 8 (0)
28 1460 811 11 (1)
29 1397 778 12 (0)
30 1373 779 11 (0)
§ Variants with MAF less than 1%, read depth more than 20 reads and a reference to allele ratio more than
0.25 were included.
* Ref 24, ** LOF = Loss of function variants.
Table 2 Effect allele frequency (EAF)
SNP Genomic
coordinates
(hg19)
Nearest gene Cases Controls OR 95% CI p-value*
rs1063318 6:32632745 HLA-DQB1 0.65 0.32 3.89 2.1804 to 6.9383 0.0001
rs7383287 6:32783086 HLA-DOB 0.40 0.17 3.22 1.7829 to 5.8025 0.0002
rs2941515 17:37813338 STARD3 0.22 0.05 4.83 2.2197 to 10.4886 0.0002
rs73296109 17:37815749 STARD3 0.22 0.05 4.83 2.2197 to 10.4886 0.0002
rs2941513 17:37818561 STARD3 0.22 0.05 4.83 2.2197 to 10.4886 0.0002
rs8738 21:37420650 SETD4 0.23 0.08 3.74 1.8120 to 7.7085 0.0007
rs11597050 10:72614524 SGPL1 0.15 0.03 5.15 2.0335 to 13.0413 0.0011
OR= Odds ratio; CI=Confident Interval
* For each SNP a p-value was calculated using Fisher exact test.
